In addition, LESW therapy has anti-fibrotic effects in the left ventricle after acute myocardial infarction by suppressed transforming growth factor (TGF)-β1 expression, which is known to promote left ventricular fibrosis7. The gene discussed is TGFB1; the disease is myocardial infarction.